Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022
April 08, 2022 13:09 ET
|
Adagene Inc.
- Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – - IND or equivalent filings planned for two new product candidates in 2022,...
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update
March 31, 2022 08:30 ET
|
Adagene Inc.
- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater...
天演宣布出席第十九届摩根士丹利全球医疗健康年会
September 02, 2021 07:45 ET
|
Adagene Inc.
中国苏州和美国旧金山, Sept. 02, 2021 (GLOBE NEWSWIRE) -- 天演药业（以下简称“公司”或“天演”）（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物制药公司，致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。公司今日宣布，天演联合创始人、首席执行官兼董事长罗培志博士将参加2021年9月9日至15日线上举行的第十九届摩根士丹利全球医疗健康年会。 ...
Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
September 02, 2021 07:45 ET
|
Adagene Inc.
SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to...
Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
August 26, 2021 07:45 ET
|
Adagene Inc.
- Established three clinical collaborations with Merck to conduct global combination trials with pembrolizumab for three clinical-stage oncology candidates - - Evidence of ADG106 efficacy with...
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)
August 19, 2021 07:00 ET
|
Adagene Inc.
SAN FRANCISCO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and...
Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board
August 12, 2021 07:45 ET
|
Adagene Inc.
SAN FRANCISCO, Calif. and SUZHOU, China, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company...
Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)
July 22, 2021 07:45 ET
|
Adagene Inc.
SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and...
Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
July 07, 2021 07:45 ET
|
Adagene Inc.
SAN FRANCISCO and SUZHOU, China, July 07, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
天演药业宣布纳入FTSE Russell指数
June 16, 2021 07:45 ET
|
Adagene Inc.
旧金山和中国苏州, June 16, 2021 (GLOBE NEWSWIRE) -- 天演药业有限公司（以下简称为“天演药业”）（纳斯达克股票代码：ADAG）是一家平台驱动型临床阶段生物制药公司，致力于改变新型抗体免疫疗法的发现和开发。该公司今天宣布，其将被添加到富时全球股权指数体系（以下简称为“GEIS”），包括富时全球总市值指数和富时新兴全盘指数，并将于6月21日生效。 FTSE...